Security
Benitec Biopharma Inc. Common Stock · BNTC
BNTCNASDAQCommon stockCurrentCIK 1808898Updated Oct 6, 2026
BNTC price & chart
Loading TradingView…
NASDAQ:BNTC on TradingView ↗About the company
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.
In the news
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
EFFECT filing
S-3 filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 182,623,000Source | 99,592,000Source | 52,210,000Source | 4,464,000Source |
| Property, Plant and Equipment, NetUSD | 178,000Source | 131,000Source | 179,000Source | 87,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 179,972,000Source | 97,744,000Source | 50,866,000Source | 2,477,000Source |
| Assets, CurrentUSD | 181,685,000Source | 98,518,000Source | 51,674,000Source | 3,729,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,595,000Source | 628,000Source | 516,000Source | 1,184,000Source |
| Operating Lease, Right-of-Use AssetUSD | 693,000Source | 860,000Source | 270,000Source | 526,000Source |
| Other Assets, NoncurrentUSD | 12,000Source | 28,000Source | 62,000Source | 97,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,610,000Source | 2,297,000Source | 4,962,000Source | 4,262,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 1,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -273,722,000Source | -228,176,000Source | -190,259,000Source | -167,889,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -963,000Source | -839,000Source | -892,000Source | -830,000Source |
| Stockholders' Equity Attributable to ParentUSD | 177,013,000Source | 97,295,000Source | 47,248,000Source | 202,000Source |
| Additional Paid in Capital, Common StockUSD | 451,695,000Source | 326,308,000Source | 238,398,000Source | 168,921,000Source |
| Liabilities and EquityUSD | 182,623,000Source | 99,592,000Source | 52,210,000Source | 4,464,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,344,000Source | 1,802,000Source | 4,924,000Source | 3,978,000Source |
| Operating Lease, Liability, CurrentUSD | 496,000Source | 354,000Source | 284,000Source | 275,000Source |
| Operating Lease, Liability, NoncurrentUSD | 266,000Source | 495,000Source | 0Source | 284,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 58,000Source | 66,000Source | 87,000Source | 136,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 26,410,000Source | 17,426,000Source | 830,000Source | 452,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -16,518,000Source | -23,588,000Source | -19,403,000Source | -18,012,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -105,000Source | -18,000Source | -179,000Source | -1,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 105,000Source | 18,000Source | 179,000Source | 1,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 98,977,000Source | 70,485,000Source | 68,029,000Source | 16,015,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 82,229,000Source | 46,928,000Source | 48,439,000Source | -1,586,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 180,086,000Source | 97,857,000Source | 50,929,000Source | 2,490,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 26,410,000Source | 17,426,000Source | 830,000Source | 452,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 120,000Source | -71,000Source | 40,000Source | -415,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 0Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 764,000Source | — | — |
| General and Administrative ExpenseUSD | 27,804,000Source | 23,433,000Source | 6,989,000Source | 6,382,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -45,546,000Source | -37,917,000Source | -21,751,000Source | -19,562,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -45,546,000Source | -37,917,000Source | -22,370,000Source | — |
| Nonoperating Income (Expense)USD | 5,646,000Source | 3,848,000Source | 739,000Source | -481,000Source |
| Operating ExpensesUSD | 51,192,000Source | 41,765,000Source | 22,490,000Source | 19,156,000Source |
| Operating Lease, ExpenseUSD | 500,000Source | 400,000Source | — | — |
| Other Nonoperating Income (Expense)USD | -43,000Source | -131,000Source | -204,000Source | -30,000Source |
| Proceeds from Issuance of Common StockUSD | 104,495,000Source | — | — | 17,884,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 75,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 0Source | -1,000Source | -3,000Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -51,192,000Source | -41,765,000Source | -22,490,000Source | -19,081,000Source |
| Other Nonoperating Income (Expense)USD | -43,000Source | -131,000Source | -204,000Source | -30,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -45,546,000Source | -37,917,000Source | -21,751,000Source | -19,562,000Source |
| Earnings Per Share, BasicUSD per share | -0.98Source | -1.05Source | -5.51Source | -14.12Source |
| Earnings Per Share, DilutedUSD per share | -0.98Source | -1.05Source | -5.51Source | -14.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 46,558,162Source | 36,209,271Source | 4,060,182Source | 1,385,818Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 46,558,162Source | 36,209,271Source | 4,060,182Source | 1,385,818Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 120,000Source | -71,000Source | 40,000Source | -415,000Source |
| General and Administrative ExpenseUSD | 27,804,000Source | 23,433,000Source | 6,989,000Source | 6,382,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -45,335,000Source | -37,183,000Source | -21,036,000Source | -18,953,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 5,569,000Source | 3,286,000Source | 904,000Source | -33,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -45,546,000Source | -37,917,000Source | -22,370,000Source | — |
| Nonoperating Income (Expense)USD | 5,646,000Source | 3,848,000Source | 739,000Source | -481,000Source |
| Operating ExpensesUSD | 51,192,000Source | 41,765,000Source | 22,490,000Source | 19,156,000Source |
| Operating Lease, ExpenseUSD | 500,000Source | 400,000Source | — | — |
| Research and Development ExpenseUSD | 23,388,000Source | 18,332,000Source | 15,609,000Source | 12,774,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 75,000Source |
Offerings
Registration 333-298927
Registration 333-293077
Filing attachments
bntc-ex99_1.htm · 8-K · 2026-10-05
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study • The BB-301 pivotal trial remains on track to begin in mid-2027 • Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study • Final pivotal study design expected to be confirmed in 1Q 2027 • Benitec will present int…
Read attachment ↗d123814dex42.htm · S-3 · 2026-09-14
Table of Contents Exhibit 4.2 BENITEC BIOPHARMA INC., Issuer AND [__________], Trustee INDENTURE Dated as of [__________], 20[__] DEBT SECURITIES Table of Contents TABLE OF CONTENTS 1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗bntc-ex4_10.htm · 10-K · 2026-09-14
Exhibit 4.10 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Benitec Biopharma Inc. (“Benitec,” “the Company,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (our “Certificate”) and our Amen…
Read attachment ↗bntc-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 2 bntc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated • A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and mee…
Read attachment ↗bntc-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 bntc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 May 14, 2026 Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update • Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month…
Read attachment ↗bntc-ex99_1.htm · 8-K · 2026-02-12
EX-99.1 2 bntc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update -The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoi…
Read attachment ↗